Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID06023576

Intensive Blood Pressure Control During Cardiotoxic Breast Cancer Treatment (PROTECT) A Randomized Controlled Trial

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-14

130

Participants Needed

7

Research Sites

25 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying whether an intensive approach to controlling high blood pressure is safe and more effective than standard treatment in lowering blood pressure and reducing the risk of heart damage during breast cancer treatment. This trial focuses on patients with breast cancer undergoing treatment with anthracycline-based chemotherapy and compares two systolic blood pressure (SBP) goals without testing specific medications. Participants are randomly assigned to one of two groups: one aiming for intensive blood pressure control with an SBP goal below 120 mm Hg, and the other aiming for standard control with an SBP goal below 140 mm Hg. Antihypertensive medications, including various types such as ACE inhibitors, beta-blockers, diuretics, and others, will be adjusted every 4 weeks for the first 3 months and then every 3 months up to 12 months. All participants receive dietary and lifestyle advice to help manage blood pressure. During the study, participants will have their blood pressure monitored at home and in clinic visits, along with echocardiograms at baseline, 6 months, and 12 months to assess heart function. Some participants may undergo cardiopulmonary exercise tests. Quality of life questionnaires and blood samples for biomarker analysis will also be collected. The main outcome measured is the change in systolic blood pressure from the start of the study to 12 months. The study lasts for one year, with regular follow-ups to evaluate treatment effects and safety.

CONDITIONS

Brief Title

A Study of Blood Pressure Control During Cancer Treatment

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Female assigned at birth
  • Biopsy-proven breast cancer (stage I-IV)
  • Planned treatment with at least 2 cycles of anthracycline-based chemotherapy, with or without HER2-targeted therapy
  • Systolic blood pressure of 130 mm Hg or higher
  • Willing and able to follow the study protocol
  • Has and is willing to use a Bluetooth-enabled mobile device with Wi-Fi or cellular connection
  • For CPET subgroup: able to complete baseline cardiopulmonary exercise test without high-risk findings
Not Eligible

You will not qualify if you...

  • Estimated glomerular filtration rate (eGFR) less than 30 ml/min/1.73m2
  • Arm circumference too large for accurate blood pressure measurement with available devices
  • Unable to measure blood pressure accurately in at least one arm (e.g., due to bilateral lymphedema)
  • Recent cardiac conditions including acute coronary syndrome within 3 months, symptomatic heart failure (NYHA class III/IV) within 6 months, history of stroke, or cardiac transplantation
  • Other medical conditions that would impair participation or adherence to interventions
  • For CPET subgroup: absolute contraindications to exercise testing, including recent heart attack, unstable angina, uncontrolled arrhythmias, severe aortic stenosis, recurrent fainting, active infections affecting heart or lungs, pulmonary embolism, thrombosis, respiratory failure, uncontrolled asthma, mental impairment preventing cooperation, and others as specified in the protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 months

Participants receive antihypertensive medications titrated to achieve specific systolic blood pressure goals during a 12-month cancer treatment period. Blood pressure management is supported by dietary and lifestyle recommendations. Participants will have seated blood pressure measurements guiding medication adjustments.

Visits every 4 weeks for the first 3 months, then every 3 months up to 12 months

Monitoring

Duration - Throughout the 12-month treatment period

Participants perform home blood pressure monitoring for 7 days at baseline, month 6, and month 12, and undergo echocardiograms at these same time points. Biomarker blood samples are collected at baseline, 3 months, and 6 months. Quality of life questionnaires are completed at baseline, 3 months, and 12 months. A subgroup of participants may complete cardiopulmonary exercise testing at baseline, 6 months, and 12 months.

Assessments at baseline, 3 months, 6 months, and 12 months; home monitoring for 7 days at baseline, 6 months, and 12 months

Trial Site Locations

Total: 7 locations

1

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States, 07920

Actively Recruiting

2

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, United States, 07748

Actively Recruiting

3

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

4

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, United States, 11725

Actively Recruiting

5

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States, 10604

Actively Recruiting

6

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States, 10065

Actively Recruiting

7

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Rockville Centre, New York, United States, 11553

Actively Recruiting

Loading map...

Research Team

A

Anthony Yu, MD

J

Jennifer Liu, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here